Co-founded by Jennifer Doudna, 2020 Nobel Prize winner in Chemistry, Intellia Therapeutics is a pioneer in the development of CRISPR/Cas9 genome editing and is rapidly moving experimental therapies towards the clinic. The company employs a modular genome editing platform to create diverse in vivo and ex vivo pipelines that span a range of therapeutic indications.
Number of employees: 51 – 250
Location: Cambridge, MA, USA
Difficulty finding data across multiple systems
Previous registration took place across SharePoint spreadsheets, emails, and paper, leading to unreliable data and outsize time spent piecing together lineages.
Tracking and updating plasmid inventory
Plasmid repositories couldn’t be tracked and kept up to date.
Inefficient request fulfillment
Lack of a formal request system led to lost requests and insufficient detail in requests. Without a reliable plasmid inventory, certain requests were difficult to complete.